M30.1 Polyarteritis with lung involvement [Churg-Strauss]

Name of the Condition

• Polyarteritis with lung involvement [Churg-Strauss]

Summary

Polyarteritis with lung involvement (Churg-Strauss) is a systemic vasculitis characterized by eosinophilic inflammation of medium and small vessels, often associated with asthma and allergic rhinitis. It involves multi-organ damage, with lung involvement being a key feature. The condition is part of the antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides and may progress to severe respiratory or systemic complications.

Causes

The exact cause is not fully understood, but it is believed to involve immune dysregulation, often triggered by allergic or autoimmune processes. Genetic predisposition and environmental factors may contribute, though no single etiology has been identified. The condition is associated with elevated eosinophils and ANCA positivity in many cases.

Risk Factors

• History of asthma or allergic rhinitis.
• Eosinophilia (elevated eosinophil count).
• ANCA positivity.
• Prior use of certain medications (e.g., leukotriene modifiers, though causality is debated).
• Male gender (slight predominance).

Symptoms

• Respiratory: cough, dyspnea, pulmonary infiltrates, or asthma exacerbations.
• Systemic: fever, weight loss, fatigue.
• Musculoskeletal: myalgia, arthralgia.
• Cutaneous: purpura, skin nodules, or livedo reticularis.
• Neurological: mononeuritis multiplex or peripheral neuropathy.
• Gastrointestinal: abdominal pain or ischemia (less common).

Diagnosis

Diagnosis requires a combination of clinical, laboratory, and histopathological findings. Key steps include: Clinical evaluation of asthma, eosinophilia, and systemic symptoms. Laboratory tests: eosinophil count, ANCA (especially perinuclear pattern), and inflammatory markers. Imaging: chest X-ray or CT to assess lung involvement (e.g., infiltrates, nodules). Biopsy of affected tissue (e.g., lung, skin, or nerve) to confirm eosinophilic vasculitis.

Treatment Options

• Corticosteroids: First-line therapy (e.g., prednisone) to reduce inflammation.
• Immunosuppressants: Cyclophosphamide or azathioprine for severe or refractory cases.
• Biologics: Mepolizumab (anti-IL-5) for eosinophilic-driven disease.
• Supportive care: Asthma management, infection prophylaxis, and organ-specific interventions.

Prognosis and Follow-Up

Prognosis depends on disease severity, organ involvement, and response to treatment. Early diagnosis and aggressive therapy improve outcomes. Long-term follow-up is essential to monitor for relapse, organ damage, or treatment-related complications (e.g., infection, malignancy). Mortality is higher with cardiac or gastrointestinal involvement.

Complications

• Severe respiratory failure or pulmonary hemorrhage.
• Cardiac involvement (e.g., myocarditis, pericarditis).
• Renal impairment or failure.
• Neurological deficits (e.g., neuropathy, stroke).
• Treatment-related toxicity (e.g., infection, bone marrow suppression).

Lifestyle & Prevention

• Optimize asthma control to reduce triggers.
• Avoid known allergens or irritants.
• Maintain regular medical follow-up for monitoring.
• Vaccinations (e.g., influenza, pneumococcal) to prevent infections.

When to Seek Professional Help

Seek immediate care for:

• Worsening respiratory symptoms (e.g., shortness of breath, chest pain).
• New neurological symptoms (e.g., weakness, numbness).
• Signs of organ dysfunction (e.g., reduced urine output, abdominal pain).
• Unexplained fever or weight loss.

Tips for Medical Coders

Document the presence of asthma, eosinophilia, ANCA status, and lung involvement (e.g., infiltrates, nodules) to support the diagnosis. Include details of biopsy confirmation or imaging findings. Ensure differentiation from other vasculitides (e.g., granulomatosis with polyangiitis) if applicable. Code M30.1 is specific to Churg-Strauss with lung involvement; do not use for isolated polyarteritis nodosa or other vasculitides.